Grifols (NASDAQ:GRFS) Shares Down 3.2%

Grifols, S.A. (NASDAQ:GRFS)’s share price traded down 3.2% during mid-day trading on Tuesday . The company traded as low as $8.94 and last traded at $8.94. 496,262 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 2,131,530 shares. The stock had previously closed at $9.24.

Grifols Trading Down 3.7 %

The firm’s 50-day moving average price is $8.14 and its 200 day moving average price is $7.28. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.80 and a current ratio of 1.68.

Grifols (NASDAQ:GRFS) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.21). Grifols had a net margin of 0.90% and a return on equity of 1.73%. The firm had revenue of $1.96 billion for the quarter. As a group, analysts anticipate that Grifols, S.A. will post 0.79 EPS for the current year.

Hedge Funds Weigh In On Grifols

Several large investors have recently added to or reduced their stakes in the company. Capital World Investors raised its holdings in shares of Grifols by 4.9% during the first quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock worth $138,605,000 after purchasing an additional 961,700 shares during the period. Brandes Investment Partners LP lifted its holdings in Grifols by 8.7% in the second quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after acquiring an additional 1,481,924 shares during the last quarter. Black Creek Investment Management Inc. boosted its stake in Grifols by 7.7% in the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock valued at $77,799,000 after acquiring an additional 881,155 shares during the period. Armistice Capital LLC grew its holdings in shares of Grifols by 18.7% during the second quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after purchasing an additional 1,244,000 shares during the last quarter. Finally, First Trust Advisors LP raised its position in shares of Grifols by 6.9% during the 4th quarter. First Trust Advisors LP now owns 4,684,749 shares of the biotechnology company’s stock worth $54,156,000 after purchasing an additional 302,380 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.